June 22, 2017

The Food and Drug Administration’s Drug Competition Action Plan begins with a public hearing on July 18 to assess the places where FDA regulations could be creating obstacles to generic access.

June 22, 2017

According to the CDC, American adults are behind on routine annual vaccinations.

June 22, 2017

Teva’s generic will be available in 75- and 150-mg dosage strengths.

June 20, 2017

The company said that it’s expecting a launch in the second-half of 2017, and that it has already submitted an application to the FDA for a junior version of Symjepi.

June 20, 2017

This launch marks the seventh product ANI has re-commercialized after acquiring a portfolio of discontinued generic abbreviated new drug applications. 

June 20, 2017

The company said that this marks its fourth first-to-market generic launch since June 2016.

June 20, 2017

The drug had U.S. sales of $15 million for the 12 months ended April 2017, Perrigo said.

June 20, 2017

The drug is indicated as an adjunctive therapy to relieve discomfort associated with acute, painful musculoskeletal conditions.

June 19, 2017
The drug is indicated for the control of serum phosphorus in patients with chronic kidney disease.
 
June 16, 2017
The company is distributing the generic in 30-, 90- and 500-count bottle sizes, and has begun shipping the product from its Kentucky distribution center.
 
June 15, 2017

CVS Health’s April survey found that 88% of respondents are somewhat or very concerned about the high cost of prescription drugs.

June 13, 2017
The Supreme Court has overturned an appeals court decision which said Sandoz had to wait 180 days under federal law after receiving Food and Drug Administration approval to launch its biosimilar of Amgen’s Neupogen (filgrastim), Zarxio (filgrastim-sndz). 
June 13, 2017
The drug had U.S. sales of approximately $2.7 billion for the 12 months ended in March, according to QuintilesIMS data.
June 13, 2017

The award recognizes character and professional accomplishments, as well as leadership in HDA, the industry and the community.

June 12, 2017

The latest report on generics cost savings, compiled by the QuintilesIMS Institute on behalf of the Association for Accessible Medicines, highlights the key role generics play in healthcare cost savings. 

June 12, 2017

The drug saw U.S. sales of $293 million for the 12 months ended April 2017, according to QuintilesIMS data.

June 12, 2017

The ophthalmic solution is a mast cell stabilizer indicated to treat ocular itching associated with allergic conjunctivitis.

June 9, 2017

According to the QuintilesIMS Institute’s 2017 Medicine Use and Spending report, Truvada had $3.1 billion in sales on an invoice price basis in 2016, ranking 17th among the top 20 medicines in the U.S. based on invoice spending.

June 6, 2017
Teva’s authorized generic is available in 5-, 10-, 15- and 20-mcg/hour strengths. 
June 2, 2017

Mylan is introducing a generic of Novartis' Reclast injection, which treats Paget's disease of the bone, and Teva's Azilect, a Parkinson’s disease treatment. 

June 2, 2017

The National Association of Chain Drug Stores and the American Pharmacists Association shared their concerns with the Trump Administration about the potential impact of drug importation on patient safety and the delivery of value-based care. 

June 1, 2017

The acquisition gives Sawai a foothold in the U.S. generics market, and the company will retain Rusty Field as the president of the company, adding the role of CEO to his duties.

May 31, 2017
Apotex, Aurobindo, Teva and Glenmark all earned approval from the regulatory to market the drug in multiple strengths.
May 31, 2017

Mallinckrodt, in an effort to focus more on branded products, is looking for a buyer for its generics division who could pay as much as $2 billion for the business, according to a Reuters report. Reuters noted that the company’s generics sales have dropped roughly 18% between 2015 and 2016 — a period during which its branded specialty sales grew by some 40%, partially through acquisitions. (Reuters)